{"id":"sct-i10a-chemo","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4650516","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"SCT-I10A is designed to modulate the immune system to recognize and attack cancer cells more effectively. When combined with chemotherapy, it aims to both reduce tumor size and prevent recurrence by leveraging the synergistic effects of both treatments.","oneSentence":"SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:40.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer"}]},"trialDetails":[{"nctId":"NCT05552807","phase":"PHASE1","title":"SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-06-15","conditions":"Head and Neck Squamous Carcinoma","enrollment":120},{"nctId":"NCT04146402","phase":"PHASE3","title":"SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-12-31","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":330},{"nctId":"NCT04229537","phase":"PHASE1","title":"Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2020-03-01","conditions":"Esophageal Squamous Cell Carcinoma, Colorectal Cancer","enrollment":60},{"nctId":"NCT04146181","phase":"PHASE2","title":"Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-10-31","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCT-I10A"],"phase":"phase_3","status":"active","brandName":"SCT-I10A+chemo","genericName":"SCT-I10A+chemo","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents. Used for Advanced solid tumors, including but not limited to metastatic colorectal cancer and gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}